# ClinicalTrials.gov record NCT00669162

> PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00669162-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00669162-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00669162-leuprolide-v1.json
- Content SHA-256: `bbff73c8b13c95e8932e201b39c561c175bf79c9956952ab37231b62fb3e2ecf`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00669162 ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

## Sources

<a id="source-ctg-observation-nct00669162-2019-07-24-2951722899ee"></a>
- **ClinicalTrials.gov record NCT00669162 · retained source version 2019-07-24:2951722899ee8f27a83841a3d632ec832a17c4ae9e41344690de16001452b52b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00669162) (`ctg-observation-nct00669162-2019-07-24-2951722899ee`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00669162." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00669162-leuprolide-v1.json SHA-256: bbff73c8b13c95e8932e201b39c561c175bf79c9956952ab37231b62fb3e2ecf.